To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment
NCT ID: NCT04821570
Last Updated: 2023-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2021-02-23
2025-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunological Responses of COVID-19 Vaccination
NCT05238467
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
NCT00062491
Screening of Cancer Patients to Assess Impact of COVID-19
NCT04373005
Fenretinide in Treating Patients With Solid Tumors
NCT00003250
Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors
NCT06475807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chemotherapy (IV and oral)
COVID-19 Vaccine
Per recommended dosing schedule
Immunotherapy
COVID-19 Vaccine
Per recommended dosing schedule
Chemotherapy + Immunotherapy
COVID-19 Vaccine
Per recommended dosing schedule
Cyclin- dependent kinase (CDK) 4/6 inhibitors
COVID-19 Vaccine
Per recommended dosing schedule
Stem Cell Transplant recipients
COVID-19 Vaccine
Per recommended dosing schedule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 Vaccine
Per recommended dosing schedule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females age ≥ 18 years
* Patients with breast cancer, lung cancer, malignant melanoma or who have undergone stem cell transplant or chimeric antigen receptor (CAR) T cell therapy for a hematologic malignancy.
Other cancer types including hematologic malignancies may be allowed if they are receiving treatments outlined in section 4.1.4
* Solid Tumor patients and those with hematologic malignancies: Currently receiving active anti-cancer therapy, or planned to start within 14 days, with intravenous cytotoxic chemotherapy (oral or intravenous), intravenous chemoimmunotherapy combination, immunotherapy alone, an oral CDK 4/6 inhibitor. (This does not apply to recipients of stem cell transplant and CAR T therapy)
* Therapy may be neo/adjuvant or for metastatic disease
* Eastern Cooperation Oncology Group (ECOG) Performance status (PS) of 0-2
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Kansas Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qamar Khan, MD
Role: PRINCIPAL_INVESTIGATOR
University of Kansas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Kansas Cancer Center, Westwood Campus
Kansas City, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT-2021-CANINE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.